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were used as denominators in the calculation of incremental CE ratios (ICER) are 
decreased frequencies of mild hypoxia, severe hypoxia and pneumonia. RESULTS: 
Frequencies of residual NMB were estimated as 51.2% 44.6% and 0.4% in SR, 
neostigmine and Bridion groups, respectively. Hypoxia rate was calculated as 27.4% 
and 11.4% in patients with and without residual NMB. Frequencies of pneumonia 
were 17.2% and 5.9% in patients with and without residual NMB. Percentage of 
patients without any complication was found to be 88.0% in Bridion group, while it 
was 73.8% and 75.7% in SR and neostigmine groups. The costs of complications 
were 126.45c and 114.56c in SR and neostigmine groups, while it was only 34.93c in 
Bridion® group. When medication cost was added, the total cost rose to 114.62c in 
Bridion® group, which was still lower than the total costs of SR and neostigmine 
groups. The rate of severe hypoxia was estimated as 7.9% in Bridion® group, while 
it was 13.5% and 12.7% in SR and neostigmine groups, respectively. Pneumonia was 
seen in 1.2% of the patients in Bridion® group, while the frequencies of pneumonia 
were 9.4% and 8.3% in SR and neostigmine groups. CONCLUSIONS: Bridion® was 
found to be dominant to both SR and neostigmine groups, in terms of decrease in 
frequencies of hypoxia and pulmonary complications.
PND23
COST-EFFECTIVENESS EVALUATION OF LEVODOPA/CARBIDOPA/
ENTACAPONE IN TREATMENT OF PARKINSON DISEASE
Yagudina R, Kulikov AU, Serpik VG
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: To conduct pharmacoeconomic evaluation of Levodopa/Carbidopa/
Entacapone (LCE) compared to standard therapy in Parkinson disease treatment. 
Standard therapy was presented by Levodopa and Carbidopa. METHODS: The cost-
effectiveness study was carried conducted. Effectiveness was measured in DALYs. 
Time horizont for cost-effectiveness analysis was 2 years. a 3% discount rate was 
used. 1 EUR = 40 RUB. RESULTS: LCE provided beneﬁ ts in effectiveness compared 
to standard therapy. LCE reduced days incapacity index twice from 44 to 21 days. 
Two year pilot study showed that LCE provided 0,83 DALY, than standard therapy 
presented 0,5 DALY. Also administration of LCE reduced daily Levodopa dose on 
68 mg. Total annual costs for LCE therapy were 158 938 (3 974 EUR) RUB. Standard 
therapy total costs varied from 129 113 RUB (3 228 EUR) to 145 422 RUB (3 636 
EUR) yearly according to disease progression grade. Indirect costs, including GDP 
losses due to temporary disability and payments for temporary disability, were 14 372 
RUB (359 EUR) for LCE and 30 113 RUB (753 EUR) for standard therapy. The cost-
effectiveness ratio for LCE was 191 492 RUB (4 787 EUR) per DALY, than for 
standard therapy it was 258 326 RUB (6 458 EUR) per DALY. CONCLUSIONS: LCE 
demonstrates lower cost-effectiveness ratio (191 492 RUB) compared to standard 
Parkinson disease therapy (258 326 RUB), therefore LCE has an advantage over 
standard therapy in terms of pharmacoeconomic evaluation.
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OBJECTIVES: Adherence to cost-effectiveness analytic guidelines requires careful 
assessment of clinical trial results to ensure the most appropriate cohort data selection. 
This study examines the impact of cohort selection on the results of the Goldberg, et 
al. 2009 cost-effectiveness study of disease-modifying therapies (DMTs) in multiple 
sclerosis (MS). METHODS: Using intent–to-treat (ITT) two-year data from pivotal 
trials, Goldberg compared cost per relapse avoided of ﬁ rst-line DMTs. However, there 
are important differences in the ITT cohorts among the trials. Due to lower than 
expected subject drop-out rates, the interferon beta-1a IM (INF-b-1a-IM) trial was 
able to meet its primary endpoint with a reduced sample size and a decision was made 
to terminate the trial early. This resulted in almost half of the 301 ITT (or “all-
patient”) cohort being on study drug for less than two years. a second, “two-year” 
172 patient cohort consisted of patients who had completed two years on drug 
therapy. Goldberg used the INF-b-1a-IM “all-patient” cohort in his cost study. To 
test the impact of this cohort selection, we recreated Goldberg’s model using the “all-
patient” relapse rate (0.67 for INF-b-1a-IM vs. 0.82 for placebo) and then substituted 
the “two-year” cohort data (relapse rate of 0.61 for INF-b-1a-IM vs. 0.90 for placebo) 
and compared results. RESULTS: This study’s cost per relapse avoided was 45% lower 
for INF-b-1a-IM while the results for the other DMTs were comparable to those 
reported by Goldberg. Ranked from most to least cost-effective, the model results were 
$77,980 for INF-b-1a-IM, $80,121 for interferon beta-1a SC, $86,572 for interferon 
beta-1b, and $87,767 for glatiramer. CONCLUSIONS: Our analysis demonstrates the 
importance of cohort selection in cost-effectiveness analyses in MS. By selecting 
comparable cohort data from patients who had completed at least two years on study 
drug, we found that INF-b-1a-IM had the lowest cost per relapse avoided of all ﬁ rst-
line DMTs.
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OBJECTIVES: Multiple sclerosis (MS) is an inﬂ ammatory, neurodegenerative condi-
tion of central nervous system with prevalence of 1 Million worldwide (age at ﬁ rst 
manifestation 20–40 years). MS may lead to permanent disability and early retirement 
even in young adults. The purpose of this analysis was to provide an economic assess-
ment of relapsing-remitting MS-treatment with Natalizumab versus Interferons and 
Copolymer in 4 European countries (Austria, Czech Republic, Slovakia, Slovenia). 
METHODS: The analysis was performed using a Markov model. The model allows 
a treatment switch due to relapse. Efﬁ cacy assessment was based on the outcome 
measure “relapse-free patients”. Costs were captured for the year 2010. Resource use 
was determined from results of a survey conducted by the Austrian MS Society and 
accurately reﬂ ects the therapeutic approach. Resource use of Czech Republic, Slovakia 
and Slovenia was determined via country-speciﬁ c research. Where country speciﬁ c 
data could not be captured, Austrian data was adjusted via Purchasing Power Parities 
(PPP). The study time horizon was 2 years. The analysis was performed from the 
perspective of the health care system of the 4 European countries. RESULTS: In Czech 
Republic the average cost of the therapy algorithm Natalizumab amount to c33,835 
per patient within the time horizon of 2 years versus c22,896 (Interferon) and c21,256 
(Copolymer). a patient successfully treated with Natalizumab accounts for c56,525 
compared to c70,190 (Interferon) and for c87,555 (Copolymer). In Slovakia a relapse-
free patient values c60,357 (Natalizumab) versus c58,043 (Interferon) and c19,921 
(Copolymer). a relapse-free patient in Slovenia values c59,108 (Natalizumab) versus 
c66,202 (Interferon) and c84,207 (Copolymer). In Austria a relapse-free patient values 
c58,423 (Natalizumab) versus c71,906 (Interferon) and c89,591 (Copolymer). CON-
CLUSIONS: In Czech Republic, Slovenia, and Austria, treatment of MS with Natali-
zumab is more cost-effective than Interferon resp. Copolymer 1 therapy. Switching to 
effective and more expensive alternatives does not account for higher health care costs.
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in 
patients with uncontrolled partial-onset seizures. METHODS: The model simulated 
the treatment pathway of a hypothetical cohort of 1000 patients over 2 years from 
the perspectives of the National Health Service (NHS) in Scotland and the Spanish 
Healthcare System (SNS) in 2008. a decision tree was split into four phases of six 
months each during which patients can become seizure free, experience a seizure 
reduction (responder deﬁ ned as ≥50% reduction in seizures), or withdraw due to 
non-response. The standard therapy arm included carbamazepine, lamotrigine, leve-
tiracetam, topiramate, and valproate. The likelihood of being in a particular health 
state has been estimated from clinical data. The cost of general practitioner visits, 
outpatient visits, hospitalizations and emergency department visits were included. 
Costs and utility values attached to various health states were taken from the published 
literature. RESULTS: Lacosamide adjunctive therapy was associated with 6730 
avoided seizures and a gain of 38 quality adjusted life-years (QALYs), compared to 
the standard therapy arm within the two-year timeframe. Treatment with lacosamide 
was associated with a cost of £113 and c107 per seizure avoided, and £20,017 and 
c22,771 per QALY gained versus standard therapy in Scotland and Spain, respectively. 
Results calculated for 6-, 12- and 18-month follow-up showed respective incremental 
cost-utility ratios of £23,479, £21,422 and £20,998 in Scotland, and c23,771, c20,703 
and c21,778 in Spain. Using a willingness-to-pay threshold of £30,000 per QALY, 
80% of the simulations in Scotland and 74.2% in Spain fell below this value after 2 
years of treatment. CONCLUSIONS: Lacosamide was shown to be a cost-effective 
adjunctive treatment in patients with uncontrolled partial-onset epilepsy in Scotland 
and Spain.
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BACKGROUND: Advanced Parkinson’s disease (APD) severely impacts the quality 
of life (QoL) for both patients and their caregiver and is associated with high health 
care and societal costs. The treatment options for those patients are limited. Duodenal 
levodopa infusion (DLI), an orphan drug, has shown to restore symptom control and 
to improve QoL substantially for both patients and their carers. OBJECTIVES: To 
evaluate the cost-utility of DLI versus standard treatment (including oral treatment 
and subcutaneous dopamine agonists) in patients with advanced PD in Sweden. 
METHODS: A stochastic Markov-based simulation model was developed. Health was 
described by 12 health states reﬂ ecting 4 categories of “OFF” time and 3 severity 
stages as measured by the Hoehn & Yahr scale. The clinical effect for both treatment 
arms was derived from published clinical trials; costs and QoL utilities were taken 
from an interim analysis of the ongoing DAPHNE study. The base case simulated 5 
years with costs/effects discounted by 3%. The societal perspective was adopted. 
RESULTS: The model estimated an improvement from 0.68 to 1.30 QALYs and a 
cost increase from 1,410,643 (c147,108) to SEK 1,674,295 (c174,603) for DLI versus 
standard treatment, leading to an incremental cost-effectiveness ratio (ICER) of 
around SEK 420,000 (c43,800) per QALY gained. The ICER for nearly 90% of the 
cohorts fell below SEK 655,000 (c68,306), the willingness-to-pay threshold often cited 
